High LRIG1 expression is associated with better prognosis for patients with Glioblastoma Multiforme
Hristina Ivanovska-Peneva,
Bulgaria
PO-1143
Abstract
High LRIG1 expression is associated with better prognosis for patients with Glioblastoma Multiforme
Authors: Hristina Ivanovska-Peneva1, Kiril Zhelev2, Zahari Zahariev2, Nicolay Conev3, George Stoyanov4, Rosen Hadgiev5, Ivan Donev6
1SHAT Oncology Varna, Department of Radiotherapy, Varna, Bulgaria; 2MHAT Uni Hospital, Department of Radiotherapy, Panagyurishte, Bulgaria; 3UMHAT St Marina, Department of Oncology, Varna, Bulgaria; 4UMHAT St Marina , Department of Clinical Pathology, Varna, Bulgaria; 5UMHAT Lozenetz, Department of Forensic Medicine, Sofia, Bulgaria; 6MHAT Nadezhda, Department of Oncology, Sofia, Bulgaria
Show Affiliations
Hide Affiliations
Purpose or Objective
Optimal treatment decisions for patients with Glioblastoma Multiforme (GBM) require reliable prognostic and predictive information. Leucine-rich repeats and immunoglobulin-like domains (LRIG1) is a transmembrane cell-surface protein, that serves as a pan-negative regulator of EGFR, MET- and RET-receptors, whose higher expression can established in astrocytic differentiation tumor samples but its precise prognostic role remains unclear in GBM.
Material and Methods
A retrospective study with patients with GBM diagnosed and treated between 2012 and 2016 was performed. A total of 74 patients with unresectable GBM in WHO IV disease, treated with Temozolomide concurrent radiotherapy, were included in this study. Expression of LRIG1 was investigated with immunohistochemistry on paraffin embedded tumor samples. The H-score was defined as: (% of cells stained at intensity category 1 x 1) + (% of cells stained at intensity category 2 x 2) + (% of cells stained at intensity category 3 x 3), giving a range of 0 to 300, where 300 was equal to 100% of tumour cells stained strongly (3 +). Then sample were classified as diffuse and perinuclear and low (≤median) and high (>median) expression levels.
Results
The cohort included 41 men (55.6%) and 33 women (44.4%), with a total mean age of 60.4 (±11.9) years. There was no significant difference in the LRIG1 expression between males and females, as well as age. There was no significant difference between patients with perinuclear expression (mean OS 8.8 months, 95% CI, 5.2 – 12.4) and diffuse expression (mean OS 7.2 months, 95% CI, 4.4 – 10.0) of LRIG1. However patients with low expression had significantly shorter OS than patients with high expression (mean OS 4.6 months, 95% CI, 3.1 – 6.1; vs mean OS 11.3 months, 95% CI, 7.4 – 15.2, respectively; log-rank test p=0.003). Moreover, in Cox regression model, the low expression of LRIG1 is associated with poor outcome (HR 2.07, 95% CI 1.2-3.4, p=0.007).
Conclusion
LRIG1 expression is a novel potential prognostic marker in patients with GBM.